beta-L-Fucp-(1->4)-[alpha-D-Glcp-(1->3)]-D-Galp

Term ID

CHEBI:148296

Synonyms

(2R,3S,4R,5S,6S)-2-[(2R,3S,4R,5R)-5,6-dihydroxy-2-(hydroxymethyl)-4-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-3-yl]oxy-6-methyloxane-3,4,5-triol
6-deoxy-beta-L-galactopyranosyl-(1->4)-[alpha-D-glucopyranosyl-(1->3)]-D-galactopyranose
alpha-D-gluco-hexopyranosyl-(1->3)-[6-deoxy-beta-L-galacto-hexopyranosyl-(1->4)]-D-galacto-hexopyranose
beta-L-fucopyranosyl-(1->4)-[alpha-D-glucopyranosyl-(1->3)]-D-galactopyranose
Glc(a1-3)[Fuc(b1-4)]Gal

Definition

A trisaccharide that is α-D-glucopyranosyl-(1→3)-D-galactopyranose in which the hydroxy group at position 4 of the galactopyranose ring has been converted into the corresponding β-L-fucopyranosyl derivative.

References

glygen:G20862VU
glytoucan:G20862VU
kegg.glycan:G03380

Ontology

ChEBI ( EBI )

Relationships

Phenotype

Phenotype resulting from beta-L-Fucp-(1->4)-[alpha-D-Glcp-(1->3)]-D-Galp

Phenotype where environments contain beta-L-Fucp-(1->4)-[alpha-D-Glcp-(1->3)]-D-Galp

Phenotype modified by environments containing beta-L-Fucp-(1->4)-[alpha-D-Glcp-(1->3)]-D-Galp

Phenotype affecting beta-L-Fucp-(1->4)-[alpha-D-Glcp-(1->3)]-D-Galp

Human Disease Model